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Abstract
In Alzheimer’s disease (AD) brains, the microtubule-associated protein tau and amyloid-b (Ab) deposit as intracellular
neurofibrillary tangles (NFTs) and extracellular plaques, respectively. Tau deposits are furthermore found in a significant
number of frontotemporal dementia cases. These diseases are characterized by progressive neurodegeneration, the loss of
intellectual capabilities and behavioral changes. Unfortunately, the currently available therapies are limited to symptomatic
relief. While active immunization against Ab has shown efficacy in both various AD mouse models and patients with AD,
immunization against pathogenic tau has only recently been shown to prevent pathology in young tau transgenic mice.
However, if translated to humans, diagnosis and treatment would be routinely done when symptoms are overt, meaning
that the histopathological changes have already progressed. Therefore, we used active immunization to target pathogenic
tau in 4, 8, and 18 months-old P301L tau transgenic pR5 mice that have an onset of NFT pathology at 6 months of age. In all
age groups, NFT pathology was significantly reduced in treated compared to control pR5 mice. Similarly, phosphorylation of
tau at pathological sites was reduced. In addition, increased astrocytosis was found in the oldest treated group. Taken
together, our data suggests that tau-targeted immunization slows the progression of NFT pathology in mice, with practical
implications for human patients.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative
disease affecting more than 35 million people worldwide [1]. It
is characterized by the loss of neurons that is associated with a
progressive decline in cognitive functions. Frontotemporal demen-
tia (FTD) describes a heterogeneous group of neurodegenerative
disorders that are characterized by a broad spectrum of clinical
symptoms including behavioural changes, language abnormalities
and motor dysfunction [2]. FTD is the second most common form
of dementia before the age of 65 [3]. Neither AD, FTD nor related
dementias can be cured, and symptomatic treatment is very
limited.
AD brains are characterized by the deposition of two hallmark
proteins, the amyloid-b (Ab) peptide and the microtubule-
associated protein tau. Ab is derived from the Ab precursor
protein (APP) and is the major constituent of plaques, while
abnormally phosphorylated (hyperphosphorylated) tau gives rise to
neurofibrillary tangles (NFTs) [4]. Ab is closely associated with the
onset of AD, but it is the tau pathology that correlates with its
severity [5].
In FTD, tau pathology occurs in the absence of overt Ab
deposition [2]. In a subset of FTD, pathogenic mutations have
been identified in the tau-encoding MAPT gene [6,7]. Transgenic
expression of mutant human tau has assisted in establishing robust
mouse models that recapitulate features of human pathology [8,9].
In addition, we and others recently showed that genetically
reducing tau levels in tau-knockout mice prevented Ab toxicity
[10,11]. Taken together, tau plays a central role in AD and FTD,
making it an attractive drug target [1].Several approaches to
therapeutically target tau have been devised [12]. However, while
effective in vitro, only a limited number of agents have undergone
testing in established transgenic models. To date only very few tau-
directed drugs have progressed into human clinical trails [12].
Given the central role of tau in disease, there is a need for new
therapeutic approaches targeting tau pathology.
Ab-directed vaccination has raised the hope for an effective
treatment for AD, and after initial setbacks in clinical trials,
modified protocols for both active and passive immunization are
back in clinical testing [13]. Although tau is an intracellular
protein and therefore does not appear as an immunization
target of first choice, active immunization of young mutant tau
transgenic mice could prevent the formation of pathology
[14,15,16]. In an effort to model the human condition at the
time of diagnosis more closely, we here used active immunization
against tau in aged tau transgenic mice with pre-existing
pathology. This reduced both tau phosphorylation and NFT
numbers, suggesting that therapeutic immunization against tau
may prevent progression of disease.
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Tau-targeted immunization in pR5 mice
Phosphorylation of tau in the P301L mutant tau expressing
pR5 line increases over time. While certain epitopes are highly
phosphorylated early on, including Ser202 (AT8) and Ser235
(AT180), others show robust phosphorylation at later, more
advanced, stages of pathology, including Ser422 and Ser396/S404
(PHF1) [17]. The latter phosphorylation sites have been associated
with NFT formation [18]. Here, we used a twelve amino acid
peptide of the human tau sequence (aa 395–406), comprising
phosphorylated Ser396/Ser404 of the PHF-1 epitope (Fig. 1 A),
to immunize P301L mutant tau expressing pR5 mice of different
ages. NFTs start to develop at 6 months of age in the amygdala of
pR5 mice and their numbers progressively increase thereafter
[18]. Therefore, the three test groups of at least eight pR5 mice
each were four, eight and 18 months old at the start of the trial,
resembling mice before the onset of (group I), with moderate
(group II) or advanced (group III) NFT pathology (Fig. 1 B). All
mice were immunized with 100 mg of KLH-linked peptide as
antigen together with CFA, followed by two additional injections
of antigen and IFA two and four weeks later (Fig. 1 B). Controls
received equivalent amounts of KLH and CFA or IFA.
Four months after the initial immunization, peptide-treated
pR5 mice developed robust titers of $1:1000, suggesting a
persistent antigen-specific immune response (Fig. 1 C). Interest-
ingly, antigen-specific titers were 1:10 in all control pR5 mice,
while the independent wild-type mice had no detectable titers.
This suggests that transgenic expression of tau is associated with a
low, but reproducible tau-specific immune response.
Immunization reduces tau phosphorylation
Mice from groups I and II were sacrificed 9 to 10 months after
the first antigen injection and processed for histopathological
analysis. Mice from group III were sacrificed 6 months after the
start of the treatment, due to their advance aged. Two control pR5
mice of group III had died by the time of analysis, and another
control mouse lost up to 30% of its body weight, different from
antigen-treated mice.
pR5 mice are characterized by a progressively increasing
phosphorylation of tau at multiple sites [17]. As outlined above,
phosphorylation of tau at the pathological sites Ser396/Ser404
(PHF-1 epitope) and Ser422 (PS422 epitope) occur late and
is closely related to NFT formation in mice [18,19]. To
determine the degree of phosphorylation of tau at Ser396/
Ser404 and Ser422, as well as total human tau expression, we
used both phosphorylation- and human tau specific antibodies.
Immunization had no overt effect on tau expression and
distribution pattern, since both human and total tau specific
antibody staining was similar in antigen-treated and control
pR5 mice (Fig. 2 A and B). Consistent with our previous
studies in pR5 mice, we found intensive somatodendritic
staining of neurons in hippocampus and amygdala of 17
months-old pR5 controls (group II) with antibodies specific to
tau phosphorylated at Ser396/Ser404 (PHF-1) or Ser422
(PS422) (Fig. 2 A and B). In addition, both PHF-1 and
PS422 stain dystrophic neurites in the amygdala and the axonal
layer of the hippocampus. In antigen-treated pR5 mice,
however, only a few neurons stain with PHF-1 or PS422.
Similarly, PHF-1 and PS422 staining of dystrophic neurites in
the hippocampus of antigen-treated pR5 mice is low compared
to controls. Hence, phosphorylation of tau at Ser396/Ser404
a n dS e r 4 2 2i sr e d u c e db yt a u - t a r g e t e di m m u n i z a t i o n .
Immunization slows progression of NFT pathology
Similar to AD brains, numbers of NFTs progressively increase
in pR5 mice after the onset of pathology [5,20]. We used Gallyas
silver impregnation to stain NFTs in pR5 paraffin sections, a
method routinely used in AD post-mortem diagnostics (Fig. 3 A).
Numbers of NFTs in the amygdala were determined on serial
sections, to determine progression of pathology as described before
[18,21]. In all three age groups, numbers of NFTs were significantly
lower in antigen-treated pR5 compared to the respective controls
Figure 1. Immune response in vaccinated P301L tau expressing
pR5 mice. (A) The longest human tau isoform (441 amino acids)
includes two N-terminal repeats, E2 and E3, (2N) and four microtubule
binding (MTB) repeats (4R). The antigen sequence (red) comprising the
phosphorylation sites (P) Ser 396 and Ser 404 lies within the C-terminal
tail region of tau. The sequence of the antigen is displayed at the
bottom. (B) Three groups I–III of pR5 mice were sequentially immunized
with KLH-linked antigen together with CFA or IFA at 0, 2 and 4 weeks.
Four months after the first injection, antibody titers were determined in
blood samples and eventually, mice were sacrificed for histopatholog-
ical analysis at indicated times. (C) Antibody titers in serum of wild-type
(wt), immunized and non-immunized (control) pR5 mice. Optic density
(OD) at 405 nm of 1:10 diluted sera shows high titers in immunized pR5
mice for all groups, low titer auto-antibodies in non-immunized pR5
controls, and no detectable antibodies in wt mice (**, p,0.001; ***,
p,0.0001).
doi:10.1371/journal.pone.0026860.g001
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comparison, NFT numbers in control pR5 mice were in agreement
with previous studies [17]. However, NFTs were present in all
antigen-treatedpR5brains,althoughatlowernumber(Fig.3B).In
particular in groups I and II, numbers of NFTs were higher than
what would have been expected if tau-targeted immunization were
to prevent de novo formation of NFTs, suggestive of a slowed rather
than halted progression of NFT pathology.
Astrocytosis in aged immunized pR5 mice
Next, we tested if there is a cellular reaction associated with the
decreased numbers of NFTs in antigen-treated pR5 mice.
Interestingly, we found a strong activation of astrocytes in the
amygdala of group III, as indicated by GFAP-positive tufted cells
(Fig. 4 A). Quantification of GFAP staining intensity revealed a
significant 2.2-fold increase in antigen-treated pR5 mice of group
III (p,0.001) compared to controls (Fig. 4 A and B). Group II
Figure 2. Tau-targeted immunization reduces tau phosphorylation in pR5 mice. (A) Immunohistochemistry (IHC) of coronal brain sections
obtained from 17 months-old pR5 mice (group II) that have been immunized 9 months ago (immunized) or were control injected (control), stained
with antibodies to total human tau (tau-13) and tau phosphorylated at Ser422 (PS422). Representative pictures from amygdala (left) and CA1 region
of the hippocampus (right) were taken at the same exposure. Several neurons stained intensively with PS422 in these brain areas of control pR5 mice
(arrowheads). Similarly, PS422 stained dystrophic neurites (arrows). In contrast, numbers of PS422-positive neurons in amygdala and hippocampus,a s
well as staining of dystrophic neurites in the hippocampus were strongly reduced in immunized pR5 mice, indicating reduced pathological
phosphorylation of tau. Note that the staining pattern with tau-13 is comparable in control and immunized pR5 amygdala and hippocampus,
suggesting similar levels of total tau. Merged pictures include nuclear DAPI staining. Scale bars, 50 mm. Graphs: Quantification of immunofluoresence
intensity in total amygdala and CA1 region of the hippocampus shows significantly reduced PS422 staining in immunized compared to control pR5
mice, while tau-13 staining is similar (**, p,0.001; ***, p,0.0001). (B) Similar to PS422, an antibody to tau phosphorylated at Ser396/Ser404 (PHF-1)
stained numerous neurons (arrowheads) and dystrophic neurites (arrows) in the amydala and hippocampus of control pR5 brains. Much less neurons
in amygdala and hippocampus and dystrophic neurites in the hippocampus stained with PHF-1 in immunized pR5 mice, indicating reduced levels of
tau phosphorylation at Ser396/Ser404. Staining for total tau (pan-tau; green) was comparable in control and immunized pR5 mice, suggesting again
unchanged total tau levels. Scale bars, 50 mm. Graphs: Quantification of immunofluoresence intensity in total amygdala and CA1 region of the
hippocampus shows significantly reduced PHF-1 staining in immunized compared to control pR5 mice, while pan-tau staining is similar (***,
p,0.0001).
doi:10.1371/journal.pone.0026860.g002
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There was no change in astrocytic GFAP staining intensity in
antigen-treated brains of group I pR5 mice, or controls of all age
groups. Numbers of GFAP-positive cells appeared increased in
control group III (Fig. 4 A and B). Taken together, aged antigen-
treated pR5 mice showed strong astrocyte activation in the
amygdala.
Discussion
In the present study, we showed that tau-targeted immunization
slows the progression of tau pathology in P301L tau transgenic
pR5 mice. Intraperitoneal injection of a peptide comprising the
Ser396/Ser404 dual phospho-epitope of tau together with CFA or
IFA, results in a persisting immune response that is associated with
decreased tau phosphorylation, reduced numbers of NFTs and –
in aged mice – astrocyte activation.
Tau-targeted immunization has been explored in different
mouse models, including independent tau transgenic lines
[14,15,16,22]. Asumi et al. used a 30 amino acid peptide
comprising the PHF-1 phospho-epitope to immunize 2 months-
old JNPL3 mice, that express P301L mutant human tau in
neurons and glia and are characterized by a rapid-progressive
NFT pathology with an age of onset of 6.5 months [14]. In these
mice, monthly immunization for up to 8 months reduced tau
phosphorylation in brain and slowed the progression of tau-related
motor deficits [14]. Therapeutic effects were less when mice were
older at the start of treatment, indicating that some deficits cannot
be restored [14]. Similar results were obtained by immunizing
mice that express all human tau isoforms together with M146L
mutant PS1 on a Mapt
-/- background [15], however, an effect on
NFT pathology in both models remains to be shown. Boimel et al.
immunized 3 months-old K257T/P301S double mutant tau-
expressing mice with a mixture of short peptides comprising the
phosphorylation sites Ser202/Thr205, Thr212/Ser214 and
Thr231, respectively [16]. By this approach, both tau phosphor-
ylation and NFT burden was significantly reduced. This is
consistent with our data of reduced NFT numbers in pR5, when
treatment was initiated at 4 months of age, before the onset of
NFT pathology. Together, both these previous and our own
studies show that tau-targeted immunization with phosphorylated
peptides reduces levels of tau phosphorylation and NFT burden in
different mouse models of tauopathy, when treatment is started
before or around the onset of NFT pathology.
However, it remained to be shown whether mice with advanced
tau pathology benefit from tau-targeted immunization. Our study
addressed this question by including mice with advanced NFT
pathology, showing that even in very old mice, progression of the
histopathological changes can be slowed by tau-targeted immu-
nization. Having a total of three experimental age groups, our data
suggests that while NFT numbers in our treatment groups I (4–
16 mo) and II (8–17 mo) suggest that immunization would only
slow the progression of the pathology, NFT numbers in group III
(18–24 mo) were similar to untreated pR5 mice at 18 months of
age, which is when treatment started. In line with a rather
preventive than clearing effect on tau pathology in younger mice
[14], our findings suggest that the treatment halts NFT formation
in aged mice. Alternatively the rate of clearance of existing NFTs
is equal to their de novo formation. However, due to the advanced
age of the mice, we cannot exclude that the shorter treatment in
group III has effects on NFT numbers. Overall, we showed that
tau-targeted immunization improves NFT pathology of aged pR5
mice. Since tau-targeted immunization improved motor deficits in
young JNPL3 mice together with reducing tau-phosphorylation
Figure 3. Tau-immunized pR5 mice have less NFTs. (A) Gallyas
silver staining of coronal brain sections from 14 (group I), 17 (group II)
and 24 (group III) months-old pR5 mice, respectively. Representative
images of amygdalae of control pR5 brains of all three groups reveal
numerous Gallyas silver-positive NFTs (‘flame shaped’), together with
dystrophic neurites. In the brains of immunized pR5 mice, there are
much less NFTs and dystrophic neurites stained, suggesting reduced
NFT pathology. Scale bar, 25 mm. (B) Quantification of NFT numbers in
serial sections from control and immunized pR5 mice stained with
Gallays silver impregnation shows significantly reduced NFT numbers in
immunized pR5 mice in all three treatment groups, compared to the
respective controls. **, p,0.001 and ***, p,0.0001; Student t-test
(controls vs. immunized); n=12 for group I and II, and n=8 for group III.
doi:10.1371/journal.pone.0026860.g003
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phosphorylation in aged pR5 mice (our study) could also improve
their deficits, although this remains to be shown.
Interestingly, we found a substantial activation of astrocytes in
aged immunized pR5 mice (group III), as indicated by increased
GFAP fluorescence intensity and morphological changes with
tufted appearance. Hence, astrocytes may have a role in reducing
tau pathology in aged pR5 mice. In the younger test groups I and
II, however, there was no overt activation of astrocytes, although
there was a trend of astrocyte activation in the intermediate
age group II. This is consistent with a previous study, where
immunization of 3 months-old K257T/P301S double mutant tau-
expressing mice did not cause astrocyte activation [16]. These
latter mice showed a slight increase in numbers of lectin-positive
microglia, but they were not activated [16]. Taken together, to
which degree the cellular response, and in particular the activation
of astrocytes contributes to the effects of tau-targeted immuniza-
tion remains to be shown. The differences in the cellular responses
between the various studies may be explained by differences in
immunization strategies (e.g. choice of peptides, target epitopes,
and adjuvant) and mouse strains used.
There are a number of possible ways how tau-targeted
immunization might slow disease progression. Firstly, antibodies
that are capable of passing the blood brain barrier (BBB) (that is
increasingly permeable with aging and in AD [23,24]) and then
enter neurons, modulating phosphorylation and/or degradation of
tau directly. This concept remains controversial, since only one
study revealed intraneuronal antibodies upon tau-targeted immu-
nization [14], while another study showed antibodies in brain
vessels, but not in neurons or brain parenchyma [16]. We did not
see labeling of neurons with secondary anti-mouse antibodies
in treated pR5 mice in the present study (data not shown).
Interestingly, tau-specific antibodies were present in non-immu-
nized pR5 mice, although titers were much lower than in
immunized animals. Similarly, auto-antibodies were found in
control JNPL3 and humanized tau mice [14,15], however, their
role remains unclear. Another possible mechanism is increased
intracellular degradation of tau mediated by tau-targeted immu-
nization. This may be supported by changes in cathepsin levels,
which point to lysosome-mediated degradation in immunized
K257T/P301S double mutant tau-expressing mice [16]. On the
other hand, total tau levels remained unchanged upon immuni-
zation of JNPL3 mice [14], and staining with total tau antibodies
was comparable in immunized and control pR5 mice (this study),
arguing against overtly increased degradation of tau. It seems
rather that tau-targeted immunization reduces the degree of tau
phosphorylation in both young [14] and aged mice (our study),
thereby possibly reducing soluble hyperphosphorylated tau species
that are increasingly recognized as toxic [25]. Finally, tau-targeted
immunization may clear specific tau species that are involved in
intercellular spreading of tau pathology and inititiation of tau
aggregation in recipient cells [25,26]. This may involve clearing
functions of astrocytes that we found to be activated in mice with
higher NFT burden upon immunization. Taken together, the
general mechanism(s) involved in the effects of tau-targeted
immunization remain to be elucidated.
Immunization targeting proteins other than tau, which also
form deposits in neurodegenerative disorders, has become an
increasingly pursued therapeutic approach. The furthest advanced
to date is Ab-based active and passive immunization in AD.
Despite some setbacks, different human trails have resulted in
some promising results [13]. Furthermore, immunization against
a-synuclein improved the pathology in a transgenic mouse model
of Lewy body disease, a heterogeneous group of human disorders
Figure 4. Tau-targeted immunization results in astrocytosis in
old, but not young pR5 mice. (A) Immunohistochemistry with a
GFAP-specific antibody stains astrocytes in brains of control and
immunized 14 (group I), 17 (group II) and 24 (group III) months-old pR5
mice. Representative images of amygdalae show similar low GFAP
staining of astrocytes in controls for all three groups, consistent with
absence of an overt astrocytosis even in aged pR5 mice. In 14 months-
old immunized pR5 mice (group I), GFAP staining is comparable to
controls, while astrocytes stain more intensive in 17 months-old
immunized pR5 (group II). In 24 months-old immunized mice (group
III), GFAP staining is much stronger than in controls, and numerous
astrocytes have adopted a tufted morphology, suggesting activation.
Scale bar, 25 mm. (B) Quantification of GFAP staining intensity in the
amygdala on serial sections of control and immunized pR5 mice revels a
significant 2.2-fold increase in 24 months-old pR5 mice of group III
compared to non-immunized pR5 controls (p,0.0001, n=8).
doi:10.1371/journal.pone.0026860.g004
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(DLB) [27]. Hence, vaccinating AD mouse models against tau fits
well into a common treatment theme of tackling neurodegener-
ation. Being effective in mice, tau targeted immunization will need
to proceed into human trials to proof efficacy.
Materials and Methods
Mice
All animal experiments have been approved by the Animal
Ethics Committee of the University of Sydney (approval number
K00/7-2009/3/5015). pR5 mice express P301L mutant human
tau (2N4R) under control of the mouse Thy1.2 promoter in
neurons [20]. Homozygous pR5 mice were used for this study.
pR5 mice are maintained on a C57Bl/6 background, and wild-
type controls were of the same genetic background.
Immunization protocol
A peptide comprising twelve amino acids (KSPVVSGDTSPR)
with serine (S) 396 and S404 being phosphorylated and linked to
keyhole limpet hemocyanin (KLH) was used as antigen (OzPep,
Australia) (Fig. 1 A). The peptide was dissolved in phosphate-
buffered saline (PBS) and mixed with either complete or
incomplete Freund’s adjuvant (CFA/IFA; Sigma, USA) at a ratio
of 1:1 (v:v) prior to intraperitoneal injection. Three groups of 4, 8
and 18 month old pR5 mice were injected with either 100 mg
peptide-KLH or KLH (controls) with CFA, followed by injections
with peptide-KLH or KLH in IFA two and four weeks later (Fig. 1
B).
Titer measurement
Four months after the initial immunization, blood was taken
from the tail vein and serum isolated by centrifugation for
antibody titer measurements using an enzyme-linked immunosor-
bant assay (ELISA). Briefly, 96-well Microlon plates (Greiner,
Germany) were coated overnight with 10 mg/ml peptide in ELISA
buffer (0.05% (v/v) Tween-20 (Sigma) in Tris-buffered saline
(pH 7.5; Sigma)), washed and then blocked with 0.25% (w/v)
bovine serum albumin (Sigma) in ELISA buffer for 30 minutes at
room temperature. Serial dilutions of sera were incubated for
2 hours at room temperature and antigen-specific antibodies were
detected with alkaline phosphatase (AP)-coupled anti-mouse
antibodies (1:159000; Sigma) and ready-to-use pNPP dye (Sigma).
The color reaction was measured at 405 nm in a Benchmark plus
plate reader (Biorad). Titers are considered as the highest dilution
with a positive assay signal.
Histology
Six months after the initial immunization, mice were anesthe-
tized and transcardially perfused with PBS followed by 4%
paraformaldehyde (PFA) in PBS. Brains were extracted and fixed
in 4% PFA/PBS over night at 4uC. Brains were then processed in
a Excelsior tissue processor (Thermo, USA), embedded in paraffin
and sectioned at 3 mm for immunohistochemistry (IHC) and
10 mm for Gallyas silver staining of NFTs. IHC and Gallyas
staining have been described before [21]. Primary antibodies were
against human tau (Tau-13, abcam), total tau (panTau, Dako), tau
phosphorylated at Ser396/Ser404 (PHF-1, P. Davies) or Ser422
(PS422, Invitrogen) and glial fibrillary acidic protein (GFAP,
Sigma). Alexa-labeled secondary antibodies to rabbit and mouse
IgG were used for visualization (1:250, Invitrogen).
Quantification of histology
Gallyas-positive NFTs were counted on serial sections as
previously described [18]. Briefly, NFTs in the amygdala were
counted on five coronal sections of 50 mm distance per brain
between the stereologic coordinates VD: 21.70 mm and 22.20
(in relation to the bregma).
Fluorescence intensity was determined as previously described
[28], using the ImageJ software (NIH) and standardized pictures of
the complete amygdala or CA1 region of the hippocampus from
serial sections as outlined above.
Statistics
Statistic analysis was done with the Prism 5.0 software
(GarphPad) using Student’s t-tests. All values are given as mean
6 standard error of the mean.
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